Spark Newswire Spark Newswire
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
News by Category
  • After-Hours Center
  • Analyst Color
  • Analyst Ratings
  • Asia
  • Asset Sales
  • Binary Options
  • Biotech
  • Bonds
  • Broad U.S. Equity ETFs
  • Buybacks
  • Cannabis
  • Commodities
  • Contracts
  • Crowdsourcing
  • Cryptocurrency
  • Currency ETFs
  • Dividends
  • Downgrades
  • Earnings
  • Earnings Beats
  • Earnings Misses
  • Econ #s
  • Economics
  • Education
  • Emerging Market ETFs
  • Emerging Markets
  • Entertainment
  • Entrepreneurship
  • Equities
  • ESG
  • ETFs
  • Eurozone
  • Events
  • Exclusives
  • FDA
  • Federal Reserve
  • Financial Advisors
  • Financing
  • Fintech
  • Forex
  • Futures
  • Gaming
  • General
  • Global
  • Government
  • Guidance
  • Health Care
  • Hedge Funds
  • Hot
  • Initiation
  • Insider Trades
  • Insurance
  • Interview
  • Intraday Update
  • IPOs
  • Large Cap
  • Latin America
  • Legal
  • Long Ideas
  • M&A
  • Macro Economic Events
  • Macro Notification
  • Management
  • Market Summary
  • Market-Moving Exclusives
  • Markets
  • Media
  • Mid Cap
  • Mining
  • Movers
  • Movers & Shakers
  • Mutual Funds
  • New ETFs
  • News
  • Offerings
  • Opinion
  • Options
  • Penny Stocks
  • Personal Finance
  • Politics
  • Pre-Market Outlook
  • Press Releases
  • Previews
  • Price Target
  • Psychedelics
  • Psychology
  • Real Estate
  • Regulations
  • REIT
  • Reiteration
  • Restaurants
  • Retail Sales
  • Reviews
  • Rumors
  • SEC
  • Sector ETFs
  • Short Ideas
  • Short Sellers
  • Signals
  • Small Business
  • Small Cap
  • Small Cap Analysis
  • Small-Cap
  • Social Media
  • SPACE
  • Specialty ETFs
  • Sports
  • Sports Betting
  • Startups
  • Stock Split
  • Success Stories
  • Tech
  • Technicals
  • Termination
  • Top Stories
  • Topics
  • Trading Ideas
  • Travel
  • Treasuries
  • Uncategorized
  • Upgrades
Spark Newswire Spark Newswire
Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
Spark Newswire Spark Newswire
Filter By Ticker
Search By Date To
Today | Yesterday | This week
Browsing Category

Biotech

Biotech

Group By Ticker
Sort By
Newest | Oldest
Read More
1 minute read
  • Biotech
  • General
  • M&A
  • News
  • Rumors

Mirati Therapeutics Note From BMO, Upside Scenario Up To $200/Share: A Takeout Is Likely To Reflect Full Valuation

By Benzinga Newsdesk
November 22, 4:55 PM
BMO Upside Scenario Up To $200/sh: A Takeout Is Likely To Reflect Full Valuation For Usage In The 1L NSCLC Setting. As We Previewed Earlier This Month, We Expect The Updated Data Presented At ESMO

MRTX

Read More
1 minute read
  • Biotech
  • FDA
  • General
  • News

‘Synlogic Gets FDA Orphan Drug Designation For Live Biotherapeutic For Treatment Of Homocystinuria’ – FDA

By Benzinga Newsdesk
November 22, 4:51 PM
Search Orphan Drug Designations and Approvals (fda.gov)

SYBX

Read More
1 minute read
  • FDA
  • News

AbbVie Highlights Blood Cancer Data From Its Growing Oncology Pipeline At The 64th ASH Annual Meeting

By Benzinga Newsdesk
November 22, 4:47 PM
-       Nearly 65 abstracts, including 15 oral presentations on 7 investigational and approved medicines across 8 cancer types, to be presented at the American Society of Hemaotology

ABBV

Read More
1 minute read
  • Biotech
  • FDA
  • General
  • News

Lucira Health Gets FDA Emergency Use Authorization For Its Combined Covid-19/Flu Test

By Benzinga Newsdesk
November 22, 4:21 PM
Lucira- COVID-19 & Flu Test-Letter of Authorization (fda.gov)

LHDX

Read More
1 minute read
  • Biotech
  • General
  • Health Care
  • Large Cap
  • Legal
  • News

AbbVie Finalizes To Pay Around $2.4B In Settlement Against US Opioid Lawsuits

By Vandana Singh
November 22, 4:01 PM
Teva Pharmaceutical Industries Ltd (NYSE:TEVA) and AbbVie Inc (NYSE:ABBV) have finalized the settlement’s terms worth over $6.6 billion to resolve several…

ABBV

Read More
3 minute read
  • Asia
  • Biotech
  • General
  • Global
  • Markets
  • Media
  • News
  • Politics
  • Top Stories

Jim Cramer Says China’s Vaccines ‘Don’t Work’ But Xi Won’t Admit It

By Adam Eckert
November 22, 3:45 PM
COVID-19 cases have spiked again in China, sparking fresh lockdown measures in the nation's capital. Jim Cramer has suggested that Chinese President Xi Jinping isn't telling the whole story. 

BNTX

Read More
2 minute read
  • Biotech
  • General
  • News

“Health And Human Services Report Says Mask Mandates Should Be Reinstated To Help ‘Long Covid'” – NYPost

By Benzinga Newsdesk
November 22, 2:17 PM
Not this again. Masks and social distancing should be mandated or encouraged in public to protect people from possible “long COVID”, a new Department of Health and Human Services report

AHPI

Read More
1 minute read
  • Biotech
  • General
  • News

Beijing Has Shut Down Parks, Museums, And Other Public Spaces As China Continues To Combat Rising Covid Cases

By Benzinga Newsdesk
November 22, 2:12 PM
 - CNBC

FXI

Read More
1 minute read
  • Biotech
  • General
  • Health Care
  • Movers
  • News
  • Penny Stocks
  • Trading Ideas

10-Year Phase 3 Trial Shows CEL-SCI’s Multikine immunotherapy Extends Lives In Head & Neck Cancer Patients

By Vandana Singh
November 22, 1:21 PM
CEL-SCI Corporation (NYSE:CVM) said that its 10-year Phase 3 trial showed that Multikine immunotherapy significantly extended the lives of patients with…

BMS

Read More
1 minute read
  • Biotech
  • General
  • News

White House Coronavirus Response Coordinator Ashish Kumar Jha Says Vaccines Effective Against New Coronavirus Subvariants

By Benzinga Newsdesk
November 22, 1:13 PM
- Reuters

AZN

Posts pagination

Previous 1 … 618 619 620 … 795 Next
Free Newsletter subscribe

Stock Market Ideas & Analysis

Stay up-to-date with the same information professionals use.
Spark Newswire Spark Newswire
  • Newswire
  • Registration
  • Log In
  • Settings
  • Privacy Policy
  • Terms of Service
© 2021 Spark Newswire
All Rights Reserved.

All news is property of their respective owners. Terms of Service